mobile-logo

Research
Publish Date : 2017-05-02
Journal of Medicinal Chemistry and Toxicology

Effect of Morin on Pharmacokinetics of Prasugrel in Rats & In Vitro Metabolic Stability Followed by UPLC Method

KAPENDRA SAHU
Kapendra Sahu1,2* and Anees A. Siddiqui1*
Article information 

Affiliation

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi (India)-110062.
  • 2National Dope Testing Laboratory, MYAS, Government of India, Lodhi Road, New Delhi (India) -110003

Corresponding Author

Kapendra Sahu., Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi (India)-110062, Tel: +91-11-26059688/5650; Fax: +91-11 27048685; E-mail: kapendra_sahu@yahoo.com

Citation

Sahu, K., et al. Effect of Morin on Pharmacokinetics of Prasugrel in Rats & In Vitro Metabolic Stability Followed by UPLC Method. (2017) J Med Chem Toxicol 2(2): 79-84.

Copy rights

© 2017 Sahu, K. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.

Keywords

Abstract

 

  The aim of present study was to investigate the effect of Morin on the pharmacokinetics of Prasugrel, a substrate of P-glycoprotein (P-gp) and Cytochrome 3A (CYP3A), in rats, and metabolic stability (high throughput) studies using human liver microsomes in UPLC. For pharmacokinetics studies, Male wistar rats were pretreated with Morin (10 mg/kg) for 1 week and on the last day, a single dose of Prasugrel (1 mg/ kg) was given orally. In another group, both morin and Prasugrel were co-administered to evaluate the acute effect of morin on Prasugrel. The control group received oral distilled water for 1 week and administered with Prasugrel on the last day. As Morin is a known inhibitor of P- Glycoprotein (P-gp) and CYP 3A, it was expected to improve the bioavailability of Prasugrel. Surprisingly, the area under the concentration–time curve and peak plasma concentration relative to control of Prasugrel were 1.50- and 1.45- fold, respectively, greater in the morin-pretreated group. However, co-administration of morin had no significant effect on these parameters. Prasugrel dosages should be accustomed to avoid concomitant for potential drug interaction when Prasugrel is used clinically in combination with morin and morin-containing dietary supplements. Apart from aforementioned merits, the results of this study are further confirmed by clinical trials.